FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML

Leukemia. 2023 Jun;37(6):1379-1383. doi: 10.1038/s41375-023-01897-x. Epub 2023 Apr 21.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • E-Selectin*
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Ligands
  • MAP Kinase Signaling System
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Receptors, CXCR4 / genetics
  • Signal Transduction
  • fms-Like Tyrosine Kinase 3

Substances

  • CXCR4 protein, human
  • E-Selectin
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Ligands
  • Protein Kinase Inhibitors
  • Receptors, CXCR4